On a Friday afternoon in January 1976, a young man in a suit and tie walked into the hallways of the UCSF microbiology department.

His name was Bob Swanson. Twenty-eight years old. Venture capitalist.

His suit was pressed, his thinning hair neatly combed. Among the casually dressed researchers drifting through the building, he looked almost unreal — like an actor who had wandered onto the wrong set. People noticed him immediately, though few knew why he was there.

The man he'd come to see was Herbert "Herb" Boyer.

Boyer was large, disheveled, and famous for wearing a denim vest the way other men are remembered for their faces. He was one of the inventors of recombinant DNA technology, the busiest scientist in the building, and almost certainly the last person who needed an interruption from a stranger in a suit.

Still, Boyer agreed to meet.

Ten minutes, he said.

Then the conversation wouldn't stop.

They left the department and walked to a nearby bar called Churchill’s. They talked over beer after beer. Three hours disappeared.

At some point, each man put in five hundred dollars on the table to cover legal fees. They signed a partnership agreement.

Swanson pulled out a piece of paper. Together, they wrote down the name of the company they were about to build: Genetic Engineering Technology. Abbreviated: Genentech.

Today, outside the Founders' Research Center at Genentech's campus in South San Francisco, there is a life-size bronze sculpture.

Boyer leans back in his chair. Swanson leans forward, mid-gesture, still making his case. A beer sits in front of each of them.

The sculptor, Larry Anderson, captured the moment, the strange, fragile instant before anything had happened, when everything was still about to.

Neither man could have known what they were setting in motion that afternoon.

The company born from that conversation would help bring recombinant human insulin to hundred millions of diabetic patients, and later pioneer entirely new forms of targeted cancer therapy.

One thousand dollars opens an industry now worth over a trillion.

And it feels possible that we are standing in a moment like that again.

The boundaries of biology are breaking open once more. AI is compressing the timescale of drug discovery. Entire scientific workflows are being rewritten in real time.

Somewhere, maybe right now, two people are sitting at a table, talking.

Ten minutes passed.

Then they couldn’t stop talking.